Gunderson Dettmer represented client Boston Pharma, a clinical stage biopharmaceutical company developing differentiated therapeutics, in its strategic license arrangement with GSK.

In the announcement, Boston Pharma CEO Robert Armstrong, Ph.D., said “We have high hopes we will have a successful outcome in the clinic that would be so compelling that GSK would be interested in pursuing the [repurchase] option.”

The Gunderson team was led by Tim Ehrlich, Peter Schoch and Joel Diamond.